Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Pasithea Therapeutics Corp. KTTA

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. Epidemiological data indicate neuropsychiatric disorders as being some of the most prevalent, devastating, and yet poorly treated illnesses.


Recent & Breaking News (NDAQ:KTTA)

Pasithea Therapeutics to Call Special Meeting of Stockholders

GlobeNewswire 4 hours ago

Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis

TheNewsWire 13 hours ago

 Investor Group Sends Letter to Pasithea Therapeutics' Board of Directors

Business Wire 5 days ago

Pasithea Therapeutics Appoints Life Sciences and Health Care Executive Alfred J. Novak to its Board of Directors

GlobeNewswire 13 days ago

Pasithea Therapeutics Further Strengthens its Scientific Advisory Board with the Appointment of Dr. Merit Cudkowicz

GlobeNewswire September 15, 2022

Pasithea Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 9, 2022

Investor Group Successful in Request to Call Special Meeting of Stockholders of Pasithea Therapeutics

Business Wire September 6, 2022

Investor Group Urges Stockholders of Pasithea Therapeutics to Vote to Call Special Meeting

Business Wire August 24, 2022

Pasithea Therapeutics to Present Results of Tolerizing Vaccine Program at Prestigious International Immunotherapy Conference

GlobeNewswire August 18, 2022

Pasithea Therapeutics Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Remitting Model of Multiple Sclerosis

GlobeNewswire August 11, 2022

Pasithea Therapeutics Urges Stockholders to Reject Activist Camac Group's Unjustified Campaign

GlobeNewswire August 2, 2022

Pasithea Therapeutics Awarded a Drug Development Research Grant

GlobeNewswire July 14, 2022

Investor Group Comments on Pasithea Therapeutics' Seemingly Defensive and Dilutive Related-Party Acquisition of Alpha-5

Business Wire June 23, 2022

Pasithea Therapeutics to Participate in the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and Beyond

GlobeNewswire June 23, 2022

Pasithea Therapeutics Acquires Alpha-5 Integrin, LLC

GlobeNewswire June 22, 2022

Pasithea Therapeutics to Present at the NobleCon18 Investor Conference 2022

GlobeNewswire April 14, 2022

Pasithea Therapeutics Announces Financial and Business Results for the Fourth Quarter and Full Year 2021 and Business Update for 2022

GlobeNewswire March 30, 2022

Pasithea Therapeutics Announces Collaboration with The Glimpse Group

GlobeNewswire March 8, 2022

Pasithea Therapeutics Announces Plans to Open Three New Clinics in the UK by Mid-2022

GlobeNewswire February 24, 2022

Pasithea Therapeutics Strengthens its Scientific Advisory Board with the Appointment of Preeminent Scientist Dr. Daniel Weinberger

GlobeNewswire February 9, 2022